Basilea Announces Filing of New Drug Submission in Canada for Alitretinoin
Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the filing of a New Drug Submission (NDS) for alitretinoin with the Therapeutic Products Directorate of Health Canada.
This submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema. Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema have also been filed in Switzerland and in several EU member states.
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs in the hospital and specialty care setting.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Dr. Barbara Zink
This press release can be downloaded from www.basilea.com
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.